<?xml version="1.0" encoding="UTF-8"?>
<p>In the past, recommended vaccines included only one influenza B lineage, chosen by the World Health Organization (WHO) based on surveillance data regarding the lineage that had been observed to dominate in the previous year; however, currently, quadrivalent vaccines containing both influenza B lineages represent the best influenza prevention strategy [
 <xref rid="B40-vaccines-07-00168" ref-type="bibr">40</xref>,
 <xref rid="B41-vaccines-07-00168" ref-type="bibr">41</xref>,
 <xref rid="B42-vaccines-07-00168" ref-type="bibr">42</xref>]. Studies have shown that the administration of quadrivalent inactivated (IIV) and live attenuated (LAIV) influenza vaccines to healthy children is effective at reducing the total burden of influenza, including preventing severe cases and saving costs due to productivity losses in parents and school absenteeism, with an acceptable level of safety and tolerability [
 <xref rid="B43-vaccines-07-00168" ref-type="bibr">43</xref>,
 <xref rid="B44-vaccines-07-00168" ref-type="bibr">44</xref>,
 <xref rid="B45-vaccines-07-00168" ref-type="bibr">45</xref>].
</p>
